1 January 2024 false Taxfiler 2024.6 false 09667722business:PrivateLimitedCompanyLtd2024-01-012024-12-31 096677222023-12-31 096677222024-01-012024-12-31 09667722business:AuditExempt-NoAccountantsReport2024-01-012024-12-31 09667722business:FilletedAccounts2024-01-012024-12-31 096677222024-12-31 09667722business:Director12024-01-012024-12-31 09667722business:RegisteredOffice2024-01-012024-12-31 096677222023-12-31 09667722core:WithinOneYear2024-12-31 09667722core:WithinOneYear2023-12-31 09667722core:ShareCapitalcore:PreviouslyStatedAmount2024-12-31 09667722core:ShareCapitalcore:PreviouslyStatedAmount2023-12-31 09667722core:SharePremiumcore:PreviouslyStatedAmount2024-12-31 09667722core:SharePremiumcore:PreviouslyStatedAmount2023-12-31 09667722core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-12-31 09667722core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-12-31 09667722core:PreviouslyStatedAmount2024-12-31 09667722core:PreviouslyStatedAmount2023-12-31 09667722business:SmallEntities2024-01-012024-12-31 09667722countries:EnglandWales2024-01-012024-12-31 09667722core:FurnitureFittings2023-12-31 09667722core:ComputerEquipment2023-12-31 09667722core:FurnitureFittings2024-01-012024-12-31 09667722core:ComputerEquipment2024-01-012024-12-31 09667722core:FurnitureFittings2024-12-31 09667722core:ComputerEquipment2024-12-31 0966772212024-01-012024-12-31 096677222023-01-012023-12-31 iso4217:GBP xbrli:pure
Company Registration No. 09667722 (England and Wales)
Leaman Life Sciences Limited Unaudited accounts for the year ended 31 December 2024
Leaman Life Sciences Limited Unaudited accounts Contents
Page
- 2 -
Leaman Life Sciences Limited Company Information for the year ended 31 December 2024
Director
Oliver Garbacz
Company Number
09667722 (England and Wales)
Registered Office
Suite 1, First Floor 1 Duchess Street London W1W 6AN England
- 3 -
Leaman Life Sciences Limited Statement of financial position as at 31 December 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Tangible assets
- 
14,000 
Current assets
Debtors
251,110 
185,314 
Cash at bank and in hand
15,749 
239,357 
266,859 
424,671 
Creditors: amounts falling due within one year
(633,077)
(137,980)
Net current (liabilities)/assets
(366,218)
286,691 
Net (liabilities)/assets
(366,218)
300,691 
Capital and reserves
Called up share capital
114 
114 
Share premium
12,747 
12,747 
Profit and loss account
(379,079)
287,830 
Shareholders' funds
(366,218)
300,691 
For the year ending 31 December 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 19 February 2025 and were signed on its behalf by
Oliver Garbacz Director Company Registration No. 09667722
- 4 -
Leaman Life Sciences Limited Notes to the Accounts for the year ended 31 December 2024
1
Statutory information
Leaman Life Sciences Limited is a private company, limited by shares, registered in England and Wales, registration number 09667722. The registered office is Suite 1, First Floor, 1 Duchess Street, London, W1W 6AN, England.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Following the decision to cease trading on 31 December 2024 (see Note 7), the director has reviewed all tangible fixed assets and concluded that they have no recoverable value. Consequently, the carrying amount of these assets has been fully written down to £nil in these financial statements.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Revenue is recognised based on the type of placement as follows: 1. Permanent Placements Turnover from permanent placements is recognised when the candidate successfully completes the agreed probationary period or after a specified number of months of employment, as outlined in the contractual terms. Invoices for these placements are typically issued upon confirmation of the candidate's continued employment after this period. 2. Temporary Placements Turnover from temporary placements is recognised at the end of each agreed period, corresponding to the completion of the placement's service. Invoices are generated periodically based on the hours or days worked as reported and agreed by the client. Revenue is only recognised when it is probable that payment will be received, and the amount can be measured reliably.
Foreign exchange
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rates of exchange ruling at the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
- 5 -
Leaman Life Sciences Limited Notes to the Accounts for the year ended 31 December 2024
Cessation of Trading and Going Concern
On 31 December 2024, the company ceased trading due to incurring significant losses and being unable to meet its obligations to creditors. As a result, the director has concluded that the company can no longer continue as a going concern. Therefore, these financial statements have been prepared on a basis other than going concern (often referred to as the break-up basis or realisation basis under UK GAAP). Reason for Cessation The company has suffered significant trading losses, causing substantial erosion of its capital. The company is unable to pay its creditors as they fall due. Consequently, the director made the decision to cease all trading activities on 31 December 2024. Impact on the Financial Statements Going Concern: As the company has ceased to trade and has no realistic prospect of securing additional funding or resuming operations, these financial statements are not prepared on a going concern basis. Measurement of Assets and Liabilities: Assets are measured at the lower of carrying amount or their estimated net realisable value. Liabilities are presented in accordance with their contractual terms and the directors’ best estimates of settlement amounts.
4
Tangible fixed assets
Fixtures & fittings 
Computer equipment 
Total 
£ 
£ 
£ 
Cost or valuation
At cost 
At cost 
At 1 January 2024
5,395 
31,657 
37,052 
Disposals
(5,395)
(31,657)
(37,052)
At 31 December 2024
- 
- 
- 
Depreciation
At 1 January 2024
2,395 
20,657 
23,052 
Charge for the year
2,000 
5,000 
7,000 
On disposals
(4,395)
(25,657)
(30,052)
At 31 December 2024
- 
- 
- 
Net book value
At 31 December 2024
- 
- 
- 
At 31 December 2023
3,000 
11,000 
14,000 
5
Debtors
2024 
2023 
£ 
£ 
Amounts falling due within one year
VAT
31,135 
39,820 
Trade debtors
37,756 
117,593 
Accrued income and prepayments
- 
24,560 
Other debtors
182,219 
3,341 
251,110 
185,314 
- 6 -
Leaman Life Sciences Limited Notes to the Accounts for the year ended 31 December 2024
6
Creditors: amounts falling due within one year
2024 
2023 
£ 
£ 
Trade creditors
167,947 
47,706 
Taxes and social security
127,759 
27,085 
Other creditors
316,150 
2,806 
Accruals
21,221 
60,383 
633,077 
137,980 
7
Post balance sheet events
Employees As a result of the cessation of trading, all employees have been made redundant. The related costs of redundancy have been included in these financial statements under Wages. Future Outlook The director is taking steps to realise the remaining assets and settle outstanding obligations. The director is in the process of appointing an insolvency practitioner.
8
Average number of employees
During the year the average number of employees was 12 (2023: 18).
- 7 -